EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
No dose-limiting toxicities, severe adverse events, or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR™platform and SCL mRNA technology EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies […]